What factors drove the changes in Infusystem's revenue and profit?

What is Infusystem's gross profit margin?

What is Infusystem's latest dividend and current dividend yield?

What were the key takeaways from Infusystem’s earnings call?

What does Infusystem do and what are its main business segments?

Did Infusystem beat or miss consensus estimates last quarter?

What guidance did Infusystem's management provide for the next earnings period?

What is the revenue and EPS growth rate for Infusystem year over year?

- **Record Financials**: Q3 2025 net revenue $36.5 million (+3.3% YoY), EBITDA $8.3 million (+5.6% YoY), and trailing 12-month EBITDA $30.2 million (21.4% margin).
- **Strategic Adjustments**: Biomedical services contract reduced revenue by $6-7 million annually but improved profitability; PCDs added $2 million in Wound Care revenue.
- **AI/automation Benefits**: New RCM system and ERP upgrade driving 57% gross margin, with Oncology revenue hitting all-time high.
- **Cash Flow Strength**: Generated $17 million in operating cash flow YTD, reduced debt by $5.7 million, and repurchased $8.6 million in shares.

**【CEO Summary Section】**
- **Revenue Growth and Strategic Initiatives**: Q3 2025 net revenue reached $36.5 million, a 3.3% year-over-year increase. Patient Services segment revenue grew 7.6%, driven by Oncology (+3.6%) and Wound Care (+116%).
- **Contract Adjustments**: Signed a biomedical services contract amendment reducing annual revenue by $6-7 million but improving operating income through cost reductions. 
- **New Revenue Streams**: Launched pneumatic compression devices (PCDs) in Wound Care, generating $2 million in Q3 revenue. Expanded AI/automation tools for billing and intake processes.

**【CFO Financial Commentary】**
- **Gross Profit**: $20.8 million (57% margin), up 9.3% YoY, driven by labor efficiency, pricing, and lower pump disposal costs.
- **EBITDA**: $8.3 million (22.8% of revenue), with trailing 12-month EBITDA at $30.2 million (21.4% margin). Generated $17 million in operating cash flow YTD, down from $10 million in capital spending.
- **Liquidity Management**: Reduced net debt by $5.7 million, repurchased $8.6 million in shares, and maintained $65 million liquidity.

**【Q&A Highlights】**
- **AI/automation Impact**: New RCM system reduced Wound Care claims processing costs; Oncology revenue hit record levels.
- **Growth Profile**: Patient Services (Wound Care, Oncology) driving 6-8% revenue growth; Device Solutions constrained by contract adjustments.
- **ERP Transition**: $770,000 in Q3 ERP upgrade expenses, with full implementation in Q1 2026.
- **Shareholder Returns**: $8.6 million in buybacks YTD, with plans to continue capital returns via buybacks and debt reduction.

InfuSystem Holdings, Inc. (INFU) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

INFU

INFU fundamentals

You can ask Aime